Syncona Regulatory News (SYNC)

Syncona Limited

Anaveon to present clinical data update

16 October 2023

Syncona Ltd, a leading healthcare company focused on creating, building and scaling a portfolio of global leaders in life science, notes that its portfolio company, Anaveon, has announced that it will present updated clinical data from the ongoing Phase I dose escalation study of ANV419 in patients with solid tumours in a poster at the European Society of Medical Oncology (ESMO) annual meeting. ANV419 is a selective interleukin-2 (IL-2) agonist, a type of protein which has the potential to therapeutically enhance a patient's immune system to respond to tumours. It has been designed to overcome known challenges with approved IL-2 therapies and enable the delivery of high dose IL-2 to patients in a way which addresses safety, tolerability and durability issues seen elsewhere in its use.

Highlights from the poster presentation include:

· Overall, ANV419 continues to demonstrate a potentially differentiated safety profile to approved IL-2 therapies

· ANV419, at a dose of 243 µg/kg every two weeks, was determined as the recommended Phase II dose

· The study determined that one injection of ANV419 at this dose level delivers more IL-2 exposure than a full cycle of an approved IL-2 therapy (high dose aldesleukin)

· A durable response was observed in one patient with advanced immunotherapy-resistant non-small cell lung cancer (NSCLC)

· Details of the poster are copied below, with further detail available in the abstract on the ESMO website

Martin Murphy, Chair of Syncona Investment Management Limited, said: "The data which will be presented at ESMO further underlines the strong safety and tolerability profile of ANV419, demonstrating potential differentiation from other IL-2 therapies. We are encouraged by the NSCLC patient who has demonstrated a durable response and now await the full efficacy read-out in the ongoing monotherapy trial in melanoma at the recommended Phase II dose."

Poster # 1031P: ANV419, a selective IL-2R?/? agonist in patients with relapsed/refractory advanced solid tumours

Authors: E. Calvo, M. Joerger, H. Läubli, J. Lopez, G. Alonso Casal, E. Corral, D. Hess, D. König, V. S. Perez, E. Gasal, S. Jethwa, D. Di Blasi, E. Garralda

Date and Time: Monday, October 23, 2023, at 11:00am-12:00pm BST / 12:00pm-1:00 pm (CEST),

The accompanying poster will be on display on the ESMO 2023 meeting platform as well as on Anaveon's website from October 23, 2023.

The announcement can be accessed on Anaveon's website at https://anaveon.com/news/ and the full text of the announcement from Anaveon is contained below.

Enquiries

Syncona Ltd

Annabel Clark / Fergus Witt

Tel: +44 (0) 20 3981 7940

FTI Consulting

Ben Atwell / Natalie Garland-Collins / Tim Stamper

Tel: +44 (0) 20 3727 1000

About Syncona

Syncona's purpose is to invest to extend and enhance human life. We do this by creating and building companies to deliver transformational treatments to patients in areas of high unmet need.

Our strategy is to create, build and scale companies around exceptional science to create a diversified portfolio of 20-25 globally leading life science businesses, across development stage, modality and therapeutic areas, for the benefit of all our stakeholders. We focus on developing treatments for patients by working in close partnership with world-class academic founders and management teams. Our balance sheet underpins our strategy enabling us to take a long-term view as we look to improve the lives of patients with no or poor treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.

Anaveon announces poster presentation at the 2023 European Society for Medical Oncology Annual Meeting

- ANV419 243 µg/kg selected as recommended Phase 2 dose for solid tumors -

Basel, October 16, 2023 - Anaveon, a clinical stage, immuno-oncology company, today announced that it will present a poster on its lead program ANV419 at the European Society of Medical Oncology (ESMO) annual meeting being held from Friday October 20, 2023, to Tuesday, October 24, 2023, in Madrid, Spain.

ANV419 is a potent and selective IL-2R?/? agonist, designed to enable the delivery of high-dose IL-2 to patients in a safe way. ANV419-001 is a first-in-human, Phase 1 dose escalation study of intravenous single agent ANV419 in patients with advanced solid tumors. Overall, ANV419 was well-tolerated, with all events being self-limiting, reversible, or manageable with standard supportive care. ANV419, at a dose of 243 µg/kg every two weeks (Q2W), was determined as the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D). At this dose, PK modeling shows that one injection of ANV419 delivers more IL-2 exposure than a full cycle of high dose aldesleukin.

The abstract is available on the ESMO website, and the accompanying poster will be on display on the ESMO 2023 meeting platform as well as on Anaveon's website from October 23, 2023.

Poster # 1031P - ANV419, a selective IL-2R?/? agonist in patients with relapsed/refractory advanced solid tumors

Authors: E. Calvo, M. Joerger, H. Läubli, J. Lopez, G. Alonso Casal, E. Corral, D. Hess, D. König, V. S. Perez, E. Gasal, S. Jethwa, D. Di Blasi, E. Garralda

The Poster will be presented on Monday, October 23, 2023, between 12:00 pm and 1:00 pm (CEST).

Anaveon is developing selective cytokine receptor agonists with the potential to therapeutically enhance a patient's immune system to respond to tumors. ANV419, currently in Phase 2 studies in multiple cancer indications, is designed to preferentially signal through the IL-2 beta/gamma receptor resulting in strong proliferation of effector cells in patients. The follow-on compound, ANV600, targets the selective IL-2 receptor moiety to tumor infiltrating lymphocytes cells and may have therapeutic benefit in less immunogenic tumors. These novel types of therapeutics, if approved, could potentially have a wide utility in oncology, including in combination with cell therapies, vaccines, checkpoint inhibitors and radiotherapy.

ENDS

Enquiries

JW Communications

Julia Wilson

Email: Julia.Wilson@anaveon.com

Tel: +44 7818 430877

About Anaveon

Anaveon is a clinical stage, biopharmaceutical company, based in Switzerland, that develops biologics to modulate the function of cytokines and provide substantial therapeutic benefit to cancer patients. Our vision is to develop novel immune therapies benefiting patients suffering from a wide variety of diseases with immune pathology. For further information please visit the Company's website at: www.anaveon.com.